The deal priced below last closing price of $17.66. Jefferies and Leerink are acting as joint book running managers for the offering.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics announces common stock offering, no amount given
- Travere Therapeutics price target raised to $27 from $23 at Scotiabank
- Travere Therapeutics price target raised to $20 from $18 at Barclays
- Travere Therapeutics Boosts Sales with FILSPARI Approval
- Travere Therapeutics reports Q3 adjusted EPS (46c), consensus (68c)